Mr. Radie joined Neuraptive Therapeutics in June 2020 as Chairman of the Board and Chief Executive Officer. Previously he served as President, Chief Executive Officer and Director of Zyla Life Sciences (formerly Egalet) from March 2012 to October 2019. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in 2011. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular, Inc. from December 2008 through March 2009.
From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick Pharmaceuticals, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. He currently serves as a member of the Board of Directors of Rockwell Medical, Inc., a biopharmaceutical company, ValSource a healthcare advisory services company, Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer, and Life Sciences of Pennsylvania, formerly Pennsylvania Bio.
Mr. Radie has served as a Director of Affinium Pharmaceuticals, Ltd., a specialty pharmaceutical company, from July 2012 to March 2014 and Veloxis Pharmaceuticals AS, a public commercial stage company from June 2016 until its acquisition in February 2020.
Mr. Radie received his B.S. in Chemistry from Boston College.